Prostate-Specific Antigen Modulatory Effect of a Fermented Soy Supplement for Patients with an Elevated Risk of Prostate Cancer: a Non-Randomized, Retrospective Observational Registration.
Phytotherapeutics
Prostate
Prostate biopsy
Prostate cancer detection
Prostate specific antigen
Journal
Current urology
ISSN: 1661-7649
Titre abrégé: Curr Urol
Pays: United States
ID NLM: 101471188
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
10
05
2019
accepted:
03
07
2019
entrez:
23
11
2020
pubmed:
24
11
2020
medline:
24
11
2020
Statut:
ppublish
Résumé
To investigate the efficacy of a 6-month fermented soy supplement (equol-containing), measured by prostate-specific antigen (PSA) stabilization or PSA decrease from baseline (PSA modulatory effect) in men with an elevated risk of prostate cancer (PCa), with a WHO performance 0-2 and a follow-up of 12 months. The patient population consisted of men with an elevated risk of PCa and a prior negative prostate biopsy within 1 year from starting therapy. Serum PSA values were recorded at inclusion (iPSA), at 6 months (1PSA), and optionally at 12 months (2PSA). Statistical analysis was carried out using the Wilcoxon rank sum test (p < 0.05). In total, 137 men used fermented soy for any prostatic reason. After inclusion criteria for an elevated risk of PCa and a prior negative prostate biopsy, we selected 58 patients. Among these, there was a significant PSA modulatory effect (iPSA-1PSA, p = 0.003). This modulatory effect was more strongly evident in the subgroup of patients with an elevated iPSA (≥ 4 ng/ml) (n = 33, iPSA-1PSA, p = 0.003, iPSA-2PSA, p = 0.002). We demonstrated a significant PSA modulatory effect of a 6-month fermented soy supplement in men with an elevated risk of PCa and a prior negative prostate biopsy. This positive effect is currently being investigated in a prospective study. Further evaluation of the role of fermented soy supplements is warranted in a preventive and therapeutic setting of men at an elevated risk of PCa.
Identifiants
pubmed: 33224007
doi: 10.1159/000499246
pii: cur-0014-0142
pmc: PMC7659407
doi:
Types de publication
Journal Article
Langues
eng
Pagination
142-149Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Références
Urology. 2004 Sep;64(3):510-5
pubmed: 15351581
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Cancer Sci. 2012 Jan;103(1):125-30
pubmed: 21988617
JAMA. 2013 Jul 10;310(2):170-8
pubmed: 23839751
Nutr Cancer. 2010;62(8):1036-43
pubmed: 21058191
Cancer Control. 2007 Jan;14(1):78-85
pubmed: 17242674
J Steroid Biochem Mol Biol. 2014 Mar;140:116-32
pubmed: 24373791
Arch Microbiol. 2010 Apr;192(4):279-87
pubmed: 20237913
Int Urol Nephrol. 2016 Sep;48(9):1453-60
pubmed: 27262851
Prostate. 2009 May 15;69(7):719-26
pubmed: 19180569
Nutr Cancer. 2011;63(6):889-98
pubmed: 21714686
Urology. 2004 Oct;64(4):765-71
pubmed: 15491717
J Nutr. 2002 Dec;132(12):3577-84
pubmed: 12468591
Am J Clin Nutr. 2009 Apr;89(4):1155-63
pubmed: 19211820
Prostate. 2004 May 1;59(2):141-7
pubmed: 15042614
Chin J Cancer. 2012 Sep;31(9):421-9
pubmed: 22085526
BJU Int. 2014 May;113(5b):E119-30
pubmed: 24053483
Prostate. 2003 Jan 1;54(1):68-78
pubmed: 12481257
J Soc Integr Oncol. 2010 Winter;8(1):3-13
pubmed: 20205984
Curr Cancer Drug Targets. 2016;16(5):455-65
pubmed: 26638886
Cancer Sci. 2016 Jul;107(7):1022-8
pubmed: 27088761
Cancer Res. 2000 Feb 1;60(3):505-9
pubmed: 10676625
Cancer Sci. 2012 Jun;103(6):969-75
pubmed: 22372745
Nutr Cancer. 2008;60(1):7-13
pubmed: 18444130
Nutr Cancer. 2003;47(2):111-7
pubmed: 15087261
Jpn J Clin Oncol. 2004 Feb;34(2):86-9
pubmed: 15067102
Urology. 2007 Jun;69(6):1102-6
pubmed: 17572195
Nutr Cancer. 2009;61(5):598-606
pubmed: 19838933